OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.299
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV